Cutaneous melanomas of the eyelid

Seminars in Ophthalmology

Volumn 21, Issue 3, 2006, Pages 195-206

  Boulos, Patrick R ^a   Rubin, Peter A D ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

Author keywords

Classification; Cutaneous; Eyelid; Immunotherapy; Lentigo maligna; Margins; Melanoma; PAM; Sentinnel lymph node; Slow Mohs

Indexed keywords

DISEASE CLASSIFICATION; EXCISION; EYELID TUMOR; HISTOPATHOLOGY; HUMAN; IMMUNOTHERAPY; LYMPH NODE BIOPSY; LYMPHATIC DRAINAGE; MALIGNANT LENTIGO; MELANOCYTOSIS; MELANOMA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; RARE DISEASE; REVIEW; SENTINEL LYMPH NODE; SKIN SURFACE; SKIN TUMOR;

EYELID NEOPLASMS; HUMANS; MELANOMA; MOHS SURGERY; RISK FACTORS; SKIN NEOPLASMS;

EID: 33747620036     PISSN: 08820538     EISSN: 17445205     Source Type: Journal    
DOI: 10.1080/08820530500353864     Document Type: Review

References (91)

1. Ajaiyeoba AI. Malignant melanoma of the eyelid in the black-case report. West African J Med 1993; 12:177-9.
2. Amato M, Esmaeli B, Ahmadi MA, et al. Feasibility of preoperative lymphoscintigraphy for identification of sentinel lymph nodes in patients with conjunctival and periocular skin malignancies. Ophthal Plast Reconstr Surg 2003; 19:102-6.
3. Andersson AP, Gottlieb J, Drzewiecki KT, et al. Skin melanoma of the head and neck. Prognostic factors and recurrence-free survival in 512 patients. Cancer 1992; 69:1153-6.
4. Armstrong BK. Epidemiology of malignant melanoma: intermittent or total accumulated exposure to the sun? J Dermatol Surg Oncol 1988; 14:835-49.
5. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma. J Clin Oncol 2001; 19:3635-48.
6. Balch CM, Houghton AN, Sober AJ, et al. 1998. Cutaneous Melanoma. 3rd ed. St. Louis: Quality Medical Publishing.
7. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer Melanoma Staging System. J Clin Oncol 2001; 19:3622-34.
8. Balch CM, Urist MM, Karakcusis CP, et al. Efficacy of 2 cm surgical margins for intermediate-thickness melanomas (1-4 mm): results of a multi-institutional randomized surgical trial. Ann Surg 1993; 218:262-7.
9. Barnhill RL, Fandrey K, Levy MA, et al. Angiogenesis and tumour progression of melanoma. Quantification of vascularity in melanocytic naevi and cutaneous malignant melanoma. Laboratory Invest 1992; 67:331-7.
10. Berwick M, Armstrong BK, Ben-Porat L, et al. Sun exposure and mortality from melanoma. J Natl Cancer Inst 2005; 97:195-9.
11. Bishop DT, Demenais F, Goldstein AM, et al. Geographical variation in the penetrance of CDKN2A mutations for melanoma. J Natl Cancer Inst 2002; 94:894-903.
12. Blessing K, McLaren KM, McLean A, Davidson P. Thin malignant melanomas (< 1.5 mm) with metastasis: a histological study and survival analysis. Histopathology 1990; 17:389-95.
13. Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 1970; 172:902-8.
14. Büttner P, Garbe C, Bertz J, et al. Primary cutaneous melanoma. Optimized cutoff points of tumor thickness and importance of Clark's level for prognostic classification. Cancer 1995; 75:2499-506.
15. Carucci JA. Intralesional interferon alfa for treatment of recurrent lentigo maligna of the eyelid in a patient with primary acquired melanosis. Arch Dermatol 2000; 136:1415-6.
16. Christenson LJ. Management of lentigo maligna. Dermatol Nursing 2004; 16:495-523.
17. Clark WH, Elder DE, Guerry DIV, et al. Model predicting survival in stage I melanoma based on tumour progression. J Natl Cancer Inst 1989; 81:1893-1904.
18. Clark WH, From L, Bernardino EA, Mihm MC. The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res 1969; 705-26.
19. Clark WH, Mihm MC. Lentigo maligna and lentigo maligna melanoma. Am J Pathol 1969; 55:39-54.
20. Cohen LM. Lentigo maligna and lentigo maligna melanoma. J Am Acad Dermatol 1995; 33:923-36.
21. Collin JRO, Garner A, Allen LH, Hungerford JL. Malignant melanoma of the eyelid and conjunctiva. Aust N Z J Ophthalmol. 1986; 14:29-34.
22. Cook BE, Bartley GB. Treatment options and future prospects for the management of eyelid malignancies. Ophthalmology 2001; 108:2088-98.
23. Cornejo P, Vanaclocha F, Polimon I, Del Rio R. intralesional interferon treatment of lentigo maligna. Arch Dermatol 2000; 136:428-30.
24. De Wit PEJ, Moretti S, Koenders PG, et al. Increasing epidermal growth factor receptor expression in human melanocytic tumour progression. J Invest Dermatol 1992; 99:168-173.
25. Dhawan SS, Wolf DJ, Rabinovitz HS, Poulos E. Lentigo maligna. Arch Dermatol 1990; 126:928-30.
26. Esmaeli B. Sentinel node biopsy as a tool for accurate staging of eyelid and conjunctival malignancies. Curr Opin Ophthalmol 2002; 13:317-23.
27. Esmaeli B, Wang B, Deavers M, et al. Prognostic factors for survival in malignant melanoma of the eyelid skin. Ophthal Plast Reconstr Surg 2000; 16:250-7.
28. Esmaeli B, Youssef A, Naderi A, et al. Margins of excision for cutaneous melanoma of the eyelid skin. Ophthal Plast Reconstr Surg 2003; 19:96-101.
29. Everall JD, Dowd PM. Diagnosis, prognosis and treatment of melanoma. The Lancet 1977; 2:286-9.
30. Fitzpatrick TB, Johnson RA, Wolff K, et al. 1997. Color Atlas and Synopsis of Clinical Dermatology, 3rd ed.. New York: McGraw-Hill.
31. Fitzpatrick TB, Szabo G. The melanocyte: cytology and cytochemistry. J Invest Dermatol.1959; 32:197-209.
32. Friedman KP, Wahl RL. Clinical use of positron emission tomography in the management of cutaneous melanoma. Semin Nucl Med 2004; 34:242-53.
33. Fuchs U, Kiuela T, Liesto K, et al. Prognosis of conjunctival melanomas in relation to histopathological features. Br J Cancer 1989; 59:261-7.
34. Gadd MA, Cosimi AB, Yu J, et al. Outcome of patients with melanoma and histologically negative sentinel lymph nodes. Arch Surg 1999; 134: 381-7.
35. Garner A, Koornneef L, Levene A, Collin JRO. Malignant melanoma of the eyelid skin: histopathology and behaviour. Br J Opthalmol 1985; 69:180-6.
36. Gershenwald JE, Colome MI, Thompson W, et al. Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol 1998; 16:2253-60.
37. Gershenwald JE, Thompson W, Mansfield PF, et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage i or ii melanoma patients. J Clin Oncol 1999; 17:976-83.
38. Glat P, Longaker MT, Jelks EB, et al. Periorbital melanocytic lesions: Excision and reconstruction in 40 patients. Plast Reconstr Surg 1998; 102:19-27.
39. Gleason JF, Bhartia PK, Herman JR, et al. Record low global ozone in 1992. Science 1993; 260:523-6.
40. Grossniklaus HE, McLean IW. Cutaneous melanoma of the eyelid. Clinicopathologic features. Ophthalmology 1991; 98:1867-73.
41. Haider SA, Thaller VT. Lid melanoma and parkinsonism. Br J Ophthalmol 1992; 76:246-7.
42. Harris MN, Shapiro RL, Roses DF. Malignant melanoma. Primary surgical management (excision and node dissection) based on pathology and staging. Cancer 1995; 75:715-25.
43. Herlyn M, Thurin J, Balaban G, et al. Characteristics of cultured human melanocytes isolated from different stages of tumor progression. Cancer Res 1985; 45:5670-6.
44. Hill DC, Gramp AA. Surgical treatment of lentigo maligna and lentigo maligna melanoma. Australasian J Dermatol 1999; 40:25-30.
45. Jelfs PL, Giles G, Shugg D, et al. Cutaneous malignant melanoma in Australia, 1989. Med J Austr 1994; 161:182-7.
46. Keilholz U, Weber J, Finke JH, et al. Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunther 2002; 25:97-138.
47. Kelly JW, Sagebiel RW, Calderon W, et al. The frequency of local recurrence and microsatellites as a guide to reexcision margins for cutaneous malignant melanoma. Ann Surg 1984; 200:759-63.
48. Kerbel RS. A cancer therapy resistant to resistance. Nature 1997; 390:335-6.
49. Kirkwood JM, Strawderman MH, Ernstoff MS, et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996; 14:7-17.
50. Koh HK, Michalik E, Sober AJ, et al. Lentigo maligna melanoma has no better prognosis than other types of melanoma. J Clin Oncol 1984; 2:994-1001.
51. Kretschmer L, Hilgers R, Möhrle M, et al. Patients with lymphatic metastasis of cutaneous malignant melanoma benefit from sentinel lymphonodectomy and early excision of their nodal disease. Eur J Cancer. 2004; 40:212-8.
52. Kumar R, Mavi A, Bural G, Alavi A. Fluorodeoxyglucose-PET in the management of malignant melanoma. Radiol Clin North Am 2005; 43:23-33.
53. Machet L, Nemeth-Normand F, Giraudeau B, et al. L'échographie ganglionnaire dans la surveillance des patients atteints de mélanome: étude monocentrique d'une cohorte de 373 patients. Ann Dermatol Venereol 2004; 131:1127.
54. Malhotra R, Chen C, Huilgol SC, et al. Mapped serial excision for periocular lentigo maligna and lentigo maligna melanoma. Ophthalmology 2003; 110:2011-8.
55. Margo CE. 2000. Pigmented lesions of the eyelid. In Albert DM, Jakobiec FA (eds.), Principles and Practices of Ophthalmology, 2nd ed., pp. 3430-46. Philadelphia: Saunders.
56. Margo CE, Duncan WC, Rich A, et al. Periocular cutaneous melanoma arising in a radiotherapy field. Ophthal Plast Reconstr Surg 2004; 20:319-20.
57. Massi D, Nardini P, De Giorgi V, Carli P. Simultaneous occurrence of multiple melanoma in situ on sun-damaged skin (lentigo maligna), solar lentigo and labile melanosis: the value of dermoscopy in diagnosis. J Eur Acad Dermatol Venereol 1999; 13:193-7.
58. McKee, PH. 1997. Pathology of the Skin with Clinical Correlations. 2nd Edition. London: Times Mirror International Publishers Limited.
59. Mcneer G, Das Gupta T. Prognosis in malignant melanoma. Surgery 1964; 56:512-8.
60. Morton DL, Wen DR, Foshag LJ, et al. Intraoperative lymphatic mapping and selective cervical lymphadenectomy for early-stage melanomas of the head and neck. J Clin Oncol 1993; 11:1751-6.
61. Munoz CM, Sanchez JL, Martin-Garcia RF. Successful treatment of persistent melanoma in situ with 5% imiquimod cream. Dermatol Surg 2004; 30:1543.
62. Naylor MF, Crowson N, Kuwahara R, et al. Treatment of lentigo maligna with topical imiquimod. Br J Dermatol 2003; 149:66-9.
63. NIH Consensus Development Panel on Early Melanoma. Diagnosis and treatment of early melanoma. J Am Med Assoc 1992; 268:1314-9.
64. Nijhawan N, Ross MI, Diba R, et al.Experience with sentinel lymph node biopsy for eyelid and conjunctival malignancies at a cancer center. Ophthal Plast Reconstr Surg 2004; 20:291-5.
65. Ostmeier H, Fuchs B, Otto F, et al. Can immunohistochemical markers and mitotic rate improve prognostic precision in patients with primary melanoma? Cancer 1999; 85:2391-9.
66. Pacifico MD, Grover R, Richman PI, et al. Development of a tissue array for primary melanoma with long-term follow-up: discovering melanoma cell adhesion molecule as an important prognostic marker. Plast Reconstr Surg 2005; 115:367-75.
67. Patel BCK, Egan CA, Lucius RW, et al. Cutaneous malignant melanoma and oculodermal melanocytosis (nevus of Ota): Report of a case and review of the literature. J Am Acad Dermatol. 1998; 38:862-5.
68. Polito E, Leccisotti A. Primary and secondary orbital melanomas: a clinical and prognostic study. Ophthal Plast Reconstr Surg 1995; 11:169-81.
69. Punt CJA. The use of interferon-alfa in the treatment of cutaneous melanoma: a review. Melanoma Res 1998; 8:95-104.
70. Reintgen DS, Cox EB, McCarty KS Jr, et al. Efficacy of elective lymph node dissection in patients with intermediate thickness primary melanoma. Ann Surg 1983; 198:379-85.
71. Robinson JK. Margin control for lentigo maligna. J Am Acad Dermatol. 1994; 31:79-85.
72. Robinson JK. Use of digital epiluminescence microscopy to help define the edge of lentigo maligna. Arch Dermatol. 2004; 140:1095-100.
73. Rodriguez-Sains RS. Melanoma of the eyelid. Plast Reconstr Surg 1999; 103:2080-1.
74. Shields JA, Shields CL. 1999. Atlas of Eyelid & Conjunctival Tumors. Philadelphia: Lippincott Williams & Wilkins.
75. Shiose S, Sakamoto T, Yoshikawa H, et al. Gene transfer of a soluble receptor of vegf inhibits the growth of experimental eyelid malignant melanoma. Invest Ophthalmol Vis Science 2000; 41:2395-403.
76. Sim FH, Taylor WF, Ivins JC, et al. A prospective randomized study of the efficacy of routine elective lymphadenectomy in management of malignant melanoma. Cancer 1978; 41:948-56.
77. Sober AJ, Chuang TY, Duvic M, et al. Guidelines of care for primary cutaneous melanoma. J Am Acad Dermatol 2001; 45:579-86.
78. Stang A, Stabenow R, Eisenger B, J̈ockel KH. Site- and gender-specific time trend analyses of the incidence of skin melanomas in the former German Democratic Republic (GDR) including 19351 cases. Eur J Cancer 2003; 39:1610-8.
79. Stannard CE, Sealy GRH, Hering ER. malignant melanoma of the eyelid and palpebral conjunctiva treated with iodine-125 brachytherapy. Ophthalmology 2000; 107:951-8.
80. Tahery DP, Goldberg R, Moy RL. Malignant melanoma of the eyelid. J Am Acad Dermatol 1992; 27:17-21.
81. Traboulsi EI, Zimmerman LE, Manz JH. Cutaneous malignant melanoma in survivors of heritable retinoblastoma. Arch Ophthalmol 1988; 106:1059-61.
82. Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med 2004; 351:998-1012.
83. Tsao H, Sober A. 2003. Acquired precursor lesions and markers of increased risk for cutaneous melanoma. In Balch C, Houghton A, Sober A, Soong S (eds.), Cutaneous Melanoma. 4th ed., 121-34. St.Louis: Quality Medical Publishing.
84. Urist MM, Balch CM, Soong SJ, et al. Head and neck melanoma in 534 clinical stage i patients. Ann Surg 1984; 200:769- 75.
85. Vaziri M, Buffam FV, Matrinka M, et al. Clinicopathologic features and behavior of cutaneous eyelid melanoma. Ophthalmology 2002; 109:901-8.
86. Veronesi U, Adamus J, Bandiera DC, et al. Inefficacy of immediate node dissection in stage 1 melanoma of the limbs. N Engl J Med 1977; 297:627-30.
87. Veronesi U, Cascinelli N, Adamus J, et al. Thin stage I primary cutaneous malignant melanoma: comparison of excision with margins of 1 or 3 cm. N Engl J Med 1988; 318:1159-62.
88. Wayte DM, Helwig EB. Melanotic freckle of hutchinson. Cancer 1968; 21:893-911.
89. Weinstock MA, Sober AJ. The risk of progression of lentigo maligna to lentigo maligna melanoma. Br J Dermatol 1987; 116:303-10
90. World Health Organization. 1992. Solar and Ultraviolet Radiation. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, vol. 55. Lyon: International Agency for Research on Cancer.
91. Yu LL, Flotte TJ, Tanabe KK, et al. Detection of microscopic melanoma metastases in sentinel lymph nodes. Cancer 1999; 86:617-27.